Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for neurodegenerative diseases, announced it will host a corporate update webinar on Sept. 2, 2026, at 4 p.m. EDT. The webinar will feature founder, President and CEO Maria Maccecchini, Ph.D., who will discuss recent progress, ongoing clinical programs and upcoming milestones, including the fully enrolled pivotal Phase 3 Alzheimer's disease (AD) trial, with top-line data and regulatory submissions expected in 2027.
The announcement comes as Annovis Bio continues to advance its pipeline for Alzheimer's and Parkinson's disease (PD). The company plans to begin enrolling patients in an AD open-label study in October 2026 to generate long-term safety data, while its PD open-label study is already underway. Additionally, discussions are ongoing regarding the initiation of a Parkinson's disease dementia program.
The webinar will be followed by a live question-and-answer session, providing investors and stakeholders an opportunity to engage directly with management. This corporate update underscores the company's commitment to transparency and its strategic focus on addressing the underlying causes of neurodegeneration.
Annovis Bio is headquartered in Malvern, Pennsylvania, and its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing these root causes, the company aims to halt disease progression and improve cognitive and motor functions in patients.
The importance of this announcement lies in the company's progress toward potential treatments for two of the most challenging neurodegenerative diseases. With the Phase 3 AD trial fully enrolled and top-line data expected in 2027, Annovis is positioning itself to potentially deliver a disease-modifying therapy that could impact millions of patients worldwide.
Investors and interested parties can view the full press release at https://ibn.fm/mls3F. For more information about Annovis Bio, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.
